文献速递造血干细胞移植与细胞治疗血栓与止血白血病

嵌合抗原受体T细胞治疗后行异基因造血干细胞移植较化疗后移植血小板植入失败与慢性移植物抗宿主病风险更高:一项倾向性评分匹配分析

Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis.
PubMed 文献 · Br J Haematol · 2025-06-04

该回顾性研究经倾向性评分匹配纳入CAR-T后移植62例与化疗后移植124例,比较两组结局。CAR-T组28天血小板植入率更低(HR=1.38,95%CI 1.02-1.87,p=0.037),中重度慢性移植物抗宿主病风险升高(HR=2.5,95%CI 1.01-6.19,p=0.048)。两组复发率、非复发死亡与生存相当。

要点

  • CAR-T后移植组28天血小板植入率低于化疗组(HR=1.38,95%CI 1.02-1.87,p=0.037)。
  • CAR-T后移植组中重度慢性移植物抗宿主病风险升高(HR=2.5,95%CI 1.01-6.19,p=0.048)。
  • 两组复发率、非复发死亡与生存无显著差异。

核心结论

  • CAR-T治疗后行异基因造血干细胞移植较化疗后移植血小板植入失败与慢性移植物抗宿主病风险更高,应谨慎对待。

研究设计与样本

  • 回顾性研究,经倾向性评分匹配后纳入既往CAR-T治疗62例与化疗124例患者,比较移植结局。

主要发现

  • CAR-T组从诊断至移植时间长于化疗组(p<0.001),移植前疾病状态更晚期(p<0.001)。
  • CAR-T组28天血小板植入率低于化疗组(HR=1.38,95%CI 1.02-1.87,p=0.037)。
  • 多因素分析显示CAR-T治疗增加中重度慢性移植物抗宿主病风险(HR=2.5,95%CI 1.01-6.19,p=0.048)。
  • CAR-T组移植相关血栓性微血管病发生率高于化疗组(6.5% vs. 0.8%,p=0.03)。
  • CAR-T组很可能/可能侵袭性真菌病发生率与化疗组相比为10.0% vs. 3.3%(p=0.08)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) has been reported to further sustain long-term leukaemia-free survival following chimeric antigen receptor T-cell (CAR-T) therapy. It remains unclear whether bridging CAR-T to allo-HSCT results in higher treatment-related toxicity and mortality. We conducted a retrospective study to compare outcomes between allo-HSCT after CAR-T or conventional chemotherapy. After propensity score matching, 62 patients with prior CAR-T therapy and 124 patients with chemotherapy were ultimately included. Patients in the CAR-T cohort had a longer duration time from diagnosis to transplant (p < 0.001) and more advanced disease status before HSCT (p < 0.001) than that of the chemotherapy cohort. Patients with prior CAR-T cell therapy had a lower 28-day platelet engraftment rates [Hazard Rate (HR) = 1.38, 95% Confidence Interval (CI), 1.02-1.87, p = 0.037]. Multivariate analysis revealed that CAR-T therapy increased the risk of moderate to severe chronic graft-versus-host disease (cGVHD) (HR = 2.5, 95% CI, 1.01-6.19, p = 0.048). Compared with patients in the chemotherapy cohort, those in the CAR-T cell cohort experienced a higher incidence of transplantation-associated thrombotic microangiopathy (6.5% vs. 0.8%, p = 0.03) and probable/possible invasive fungal disease (10.0% vs. 3.3%, p = 0.08). The relapse rate, non-relapse mortality, and survival were comparable between cohorts. Caution should be exercised in allo-HSCT following CAR-T therapy because of the higher risk of platelet engraftment failure and cGVHD compared to chemotherapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yang L, Lai X, Liu L, et al. Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis. Br J Haematol. 2025. PMID: 40464130. doi:10.1111/bjh.20180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。